NLTX | Neoleukin Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	N/A - N/A
52 Week Range	N/A - N/A
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	N/A
Average Volume	N/A
Shares Outstanding	N/A
Market Cap	N/A
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2014-03-07

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	N/A
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	7
Country	USA
Website	NLTX

Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.

NLTX's peers: ACHV, ALGS, ALLK, ARQT, ARWR, ASMB, ATHA, BOLT, PMCB, CHRS, CKPT, CMMB, CNTB, CNTX, CRBP, CTMX, CYCC, DSGN, EQ, GLPG, GLTO, GLYC, KNSA, KOD, KPTI, KRON, LCTX, LRMR, LVTX, LYRA, MEIP, MIST, MTNB, NKTR, NLSP, NUVB, NXTC, OVID, PRQR, PRTC, PULM, RLMD, SPRC, SPRO, SRZN, TBPH, TIL, TRVI, UBX, VALN, VINC, VNDA, WVE, SNTI, QNCX, IMNN, DOMH

*Chart delayed

Analyzing fundamentals for NLTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see NLTX Fundamentals page.

Watching at NLTX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on NLTX Technicals page.